- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01892891
Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing (VBY036P1B)
December 27, 2013 updated by: Virobay Inc.
A Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects
VBY-036 may treat or prevent nerve pain.
This study aims to find the highest safe and tolerable dose of VBY-036 in healthy volunteers.
Volunteers will be randomly selected to receive either a placebo or VBY-036 (30, 100, 300, 600 or 900 mg) once daily for seven days in a row.
Study Overview
Detailed Description
Detailed description is noted in Brief Summary.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Evansville, Indiana, United States, 47710
- Covance Evansville
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, 18-60 years old
- Screening body mass index between 18-32 kg/m2
- Good health, no clinically significant findings in medical history, 12-lead ECG, & vital signs;
- Clinical lab evaluations (Chem panel [fasted at least 8 hrs], CBC, HbA1c & UA in reference range for test lab (unless deemed not clinically significant);
- Negative test for drugs of abuse at Screening & at Check-in (includes alcohol);
- Negative hepatitis, HIV & TB screens;
- Females non-pregnant, non-lactating, & either postmenopausal for at least 1 year, surgically sterile for at least 90 days prior to Check-in, or agree to use from the time of consent until 90 days after Study Completion an effective form of contraception. For all females, a pregnancy test result must be negative at Screening & Check-in.
- Males will be sterile or agree to use from Check-in until 90 days following discharge an effective method of contraception.
- Able to comprehend & willing to sign Informed Consent Form
Exclusion Criteria:
- Females pregnant or nursing, or childbearing potential but unwilling to use contraception.
- History of renal or hepatic impairment; stomach or intestinal surgery or resection, malabsorption syndrome, cholecystectomy, or gastro-intestinal dysfunction that would alter absorption &/or excretion of orally administered drugs (appendectomy or hernia repair allowed);
- Anemia (hemoglobin <11.5 g/dL for females; < 13 g/dL for males) or blood donation within 8 weeks of Check-in;
- Plasma donation within 4 weeks of Check-in;
- History of alcoholism or drug addiction within 6 months to Check-in;
- Use of drugs of abuse or prescription drugs for recreational use 6 months prior to Check-in;
- Use of any tobacco-containing or nicotine-containing products 6 months prior to Check-in & during study;
- Participation in another drug trial 30 days of Check-in (within 8 weeks if previous investigational drug has immunomodulary effects, other than cathepsin S inhibition);
- History or clinical manifestations of metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders
- History of hypersensitivity or allergies to any drug compound
- History or presence of abnormal ECG
- Laboratory abnormality deemed clinically significant;
- Use of or inability to discontinue any prescription medications/products 14 days prior to Check-in & during study;
- Use of certain over-the-counter, non-prescription preparations are permitted up to 3 days before first dose;
- Use of alcohol-containing, grapefruit-containing, star fruit containing foods or beverages or "energy drinks" 72 hours to Check-in & during study;
- Poor peripheral venous access;
- Receipt of blood products 6 months to Check-in
- Subjects with history of Gilbert's Syndrome;
- Strenuous activities 48 hours to Check-in
- Illness 5 days to drug administration
- Any acute or chronic condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VBY-036
VBY-036 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
|
Cathepsin S inhibitor
|
Placebo Comparator: Placebo comparator
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Highest safe and tolerated VBY-036 dose
Time Frame: 7 days of dosing
|
Single dose of VBY-036 given daily for 7-days in a row for each cohort in an ascending manner. Cohort B1 with 30 mg dose or placebo; Cohort B2 with 100 mg dose or placebo; Cohort B3 with 300 mg dose or placebo; Cohort B4 with 600 mg dose or placebo; Cohort B5 with 900 mg dose or placebo |
7 days of dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmation of cathepsin-S inhibition
Time Frame: 7 days
|
Based on the accumulation of Iip 10 and/or cathepsin S protein levels
|
7 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The blood level of VBY-036
Time Frame: 7 days
|
The blood level of VBY-036 across the dose range of 30 mg to 900 mg
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
July 1, 2013
First Submitted That Met QC Criteria
July 1, 2013
First Posted (Estimate)
July 8, 2013
Study Record Updates
Last Update Posted (Estimate)
December 31, 2013
Last Update Submitted That Met QC Criteria
December 27, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- VBY-036-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on VBY-036
-
Virobay Inc.CompletedHealthyUnited States
-
Shanghai Zhimeng Biopharma, Inc.Recruiting
-
Virobay Inc.CompletedChronic Hepatitis C InfectionUnited States
-
Shanghai Zhimeng Biopharma, Inc.Not yet recruiting
-
Virobay Inc.LEO PharmaCompleted